A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma
Authors
Keywords
Melanoma, Stage IV, Biomarkers, VEGF, Tregs, TH1/TH2 ratio, CD4+/CD8+ ratio, LDH
Journal
SpringerPlus
Volume 4, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-04-17
DOI
10.1186/s40064-015-0951-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients
- (2013) Agnieszka Piechnik et al. INTERNATIONAL JOURNAL OF CANCER
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
- (2013) Howard L. Kaufman et al. Nature Reviews Clinical Oncology
- Neuropilin 1 guides regulatory T cells into VEGF-producing melanoma
- (2013) Wiebke Hansen OncoImmunology
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential actions of glycodelin-A on Th-1 and Th-2 cells: a paracrine mechanism that could produce the Th-2 dominant environment during pregnancy
- (2011) Cheuk-Lun Lee et al. HUMAN REPRODUCTION
- Selective Changes in the Immune Profile of Tumor-Draining Lymph Nodes After Different Neoadjuvant Chemoradiation Regimens for Locally Advanced Cervical Cancer
- (2010) Alessandra Battaglia et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evidence of Systemic Th2-Driven Chronic Inflammation in Patients with Metastatic Melanoma
- (2009) W. K. Nevala et al. CLINICAL CANCER RESEARCH
- LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)
- (2009) Sanjiv S. Agarwala et al. EUROPEAN JOURNAL OF CANCER
- Neuropilin‐1 is not a marker of human Foxp3+Treg
- (2009) Pierre Milpied et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy
- (2009) Marianna Sabatino et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma
- (2008) Domingo G. Perez et al. CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More